<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416377</url>
  </required_header>
  <id_info>
    <org_study_id>CCLG-HD-9201</org_study_id>
    <secondary_id>CDR0000454741</secondary_id>
    <secondary_id>EU-20586</secondary_id>
    <nct_id>NCT00416377</nct_id>
  </id_info>
  <brief_title>Radiation Therapy or Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma</brief_title>
  <official_title>Hodgkin's Disease Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer and Leukaemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill cancer cells. Drugs used in&#xD;
      chemotherapy work in different ways to stop the growth of cancer cells, either by killing the&#xD;
      cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy)&#xD;
      may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well radiation therapy or combination&#xD;
      chemotherapy work in treating young patients with Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Maintain the present satisfactory results of patients treated on protocol UKCCSG-HD-8201&#xD;
           in pediatric patients with stage I-III Hodgkin's lymphoma treated with radiotherapy or&#xD;
           combination chemotherapy comprising chlorambucil, procarbazine hydrochloride,&#xD;
           prednisolone, vinblastine followed by doxorubicin hydrochloride, bleomycin, vincristine,&#xD;
           and dacarbazine.&#xD;
&#xD;
        -  Determine, by comparison with UKCCSG-HD-8201, if mediastinal irradiation can be safely&#xD;
           omitted from the management of pediatric patients with Hodgkin's lymphoma and bulky&#xD;
           mediastinal disease.&#xD;
&#xD;
        -  Determine if gallium scanning of the mediastinum after chemotherapy will identify&#xD;
           patients with residual active mediastinal disease.&#xD;
&#xD;
        -  Improve disease control in patients with stage IV Hodgkin's lymphoma and slow responders&#xD;
           by intensifying treatment to patients who fail to achieve complete remission after 4&#xD;
           courses of chlorambucil, vinblastine, procarbazine hydrochloride, and prednisone.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to stage of disease&#xD;
      (I vs II-IV).&#xD;
&#xD;
        -  Stage I: Patients undergo involved-field radiotherapy.&#xD;
&#xD;
        -  Stage II-IV:&#xD;
&#xD;
             -  CHLVPP chemotherapy: Patients receive CHLVPP chemotherapy comprising oral&#xD;
                chlorambucil, oral procarbazine hydrochloride, and oral prednisolone on days 1-14&#xD;
                and vinblastine IV on days 1-8. Treatment repeats every 28 days for 2 courses.&#xD;
                Patients achieving complete resolution (CR) of measurable disease receive an&#xD;
                additional 4 courses of CHLVPP. Patients with no response or progressive disease&#xD;
                proceed to ABVD chemotherapy. Patients with shrinkage of measurable disease to &lt;&#xD;
                50% original dimensions (GPR) receive 2 additional courses of CHLVPP. Patients&#xD;
                achieving CR or GPR after completion of 2 additional courses of CHLVPP receive 4&#xD;
                more courses of CHLVPP. Patients achieving shrinkage of measurable disease to â‰¥ 50%&#xD;
                of original dimension (PR) after 2 additional courses of CHLVPP OR patients not&#xD;
                achieving CR after a total of 8 courses of CHLVPP proceed to ABVD chemotherapy.&#xD;
&#xD;
             -  ABVD chemotherapy: Patients receive ABVD chemotherapy comprising doxorubicin&#xD;
                hydrochloride IV over 4 hours and bleomycin IV, vincristine IV, and dacarbazine IV&#xD;
                on days 1 and 15. Treatment repeats every 28 days for 4-6 courses in the absence of&#xD;
                disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Mediastinal mass: Patients receive chemotherapy as per stages II-IV. Patients presenting&#xD;
           with airway or superior vena cava obstruction may also undergo radiotherapy. Patients&#xD;
           achieving CR after completion of chemotherapy receive no further treatment. Patients&#xD;
           achieving GPR or PR after completion of chemotherapy undergo gallium scan and CT scan of&#xD;
           thorax with or without biopsy at the investigator's discretion.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 353 patients were accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">353</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bleomycin sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chlorambucil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>procarbazine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed childhood Hodgkin's lymphoma by lymph node biopsy&#xD;
&#xD;
               -  Any stage disease&#xD;
&#xD;
               -  Patients with bilateral upper cervical disease with no evidence of&#xD;
                  supraclavicular, thoracic inlet, or Waldeyers ring involvement are treated as&#xD;
                  having stage I disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm^3&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Barrett</last_name>
    <role>Study Chair</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Judith E. Kingston, MD</last_name>
    <affiliation>St. Bartholomew's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Martin, MD</last_name>
    <affiliation>Royal Liverpool Children's Hospital, Alder Hey</affiliation>
  </overall_official>
  <verification_date>December 2006</verification_date>
  <study_first_submitted>December 27, 2006</study_first_submitted>
  <study_first_submitted_qc>December 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2006</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <keyword>stage I childhood Hodgkin lymphoma</keyword>
  <keyword>stage II childhood Hodgkin lymphoma</keyword>
  <keyword>stage III childhood Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
    <mesh_term>Chlorambucil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

